{
    "clinical_study": {
        "@rank": "158162", 
        "acronym": "NT-proBNP", 
        "arm_group": [
            {
                "arm_group_label": "Respiratory distress group", 
                "description": "Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7."
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7."
            }
        ], 
        "biospec_descr": {
            "textblock": "Urine NT-proBNP"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "There is a need for a biochemical marker in addition to clinical condition which will help\n      the physician to understand the clinical progress of the disease.\n\n      Urine Nt-proBNP, which does not need any blood sampling and can be collected easily, has not\n      been evaluated for respiratory distress in newborn.\n\n      The investigators aim to evaluate the prognostic value of urine NT-proBNP in respiratory\n      diseases in newborns by a controlled trial."
        }, 
        "brief_title": "Urine NT-ProBNP in Neonatal Respiratory Distress", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neonatal Respiratory Distress", 
        "condition_browse": {
            "mesh_term": "Respiratory Distress Syndrome, Newborn"
        }, 
        "detailed_description": {
            "textblock": "Neonatal diseases such as respiratory distress and transient tachypnea of newborn may\n      require high level of intensive care. On the other hand, some minor difficulties in\n      respiration can resolve within hours. Therefore, there is a need for a biochemical marker in\n      addition to clinical condition which will help the physician to understand the clinical\n      progress of the disease.\n\n      Serum NT-ProBNP level has been evaluated in transient tachypnea of newborn and found\n      compatible with the clinical progress. Urine NT-proBNP has recently been evaluated in patent\n      ductus arterioses and found compatible with the cardiac progress. However, urine Nt-proBNP,\n      which does not need any blood sampling and can be collected easily, has not been evaluated\n      for respiratory distress in newborn.\n\n      The investigators aim to evaluate the prognostic value of urine NT-proBNP in respiratory\n      diseases in newborns by a controlled trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  study group; newborns who are admitted to the neonatal intensive care unit within\n             first 2 days of life and have transient tachypnea of newborn or respiratory distress\n             syndrome signed informed consent form\n\n          -  Control Group: Newborns without any respiratory distress\n\n        Exclusion Criteria:\n\n          -  any cardiac anomaly sepsis acute renal insufficiency syndromic cases low APGAR score\n             at 5th minute (<7) lung malformations no informed consent inability in collection of\n             urine"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "7 Days", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Newborns with first postnatal 2 days with or without respiratory distress"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020993", 
            "org_study_id": "NT-proBNP Trial"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Nt-proBNP, newborn, preterm", 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "contact": {
                "email": "doktorduranyildiz@hotmail.com", 
                "last_name": "Duran Yildiz, MD", 
                "phone": "+903125957459"
            }, 
            "facility": {
                "address": {
                    "city": "Ankara", 
                    "country": "Turkey", 
                    "zip": "06300"
                }, 
                "name": "Ankara University"
            }, 
            "investigator": {
                "last_name": "Duran Yildiz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Prognostic Value of Urine NT-ProBNP in Neonatal Respiratory Distress", 
        "overall_contact": {
            "email": "doktorduranyildiz@hotmail.com", 
            "last_name": "Duran Yildiz, MD", 
            "phone": "+903125957459"
        }, 
        "overall_official": {
            "affiliation": "Ankara University", 
            "last_name": "Beg\u00fcm Atasay, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Severity of respiratory distress will be evaluated by requirement of supportive treatment such as continuous positive airway pressure, need of intubation, mechanical ventilation  and duration of support (hours)", 
            "measure": "severity of respiratory distress", 
            "safety_issue": "No", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020993"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ankara University", 
            "investigator_full_name": "Duran Yildiz", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Ankara University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ankara University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}